Displaying drugs 10776 - 10800 of 11778 in total
Mivelsiran
Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).
Investigational
Matched Description: … Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients …
XL019
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Matched Description: … XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. …
Succinobucol
AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary artery disease.
Investigational
Matched Description: … AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered …
Methylthioinosine
An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Experimental
Matched Description: … An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. …
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Matched Description: … IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia …
MK-0482
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
Matched Description: … MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT …
KF-0210
KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
Investigational
Matched Description: … KF-0210 is a small molecule developed by Keythera Pharmaceuticals. …
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
PSN9301
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
Matched Description: … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical …
LG-100268
LG-100268 is a retinoid X receptor (RXR) selective compound.
Experimental
Matched Description: … LG-100268 is a retinoid X receptor (RXR) selective compound. …
Isoliquiritigenin
Isoliquiritigenin is a precursor to several flavonones in many plants.
Experimental
Matched Description: … Isoliquiritigenin is a precursor to several flavonones in many plants. …
Cannabinol
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Matched Description: … Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa. …
BREN-02
BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).
Investigational
Matched Description: … BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1). …
CALY-002
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
BBP-671
BBP-671 is a small molecule activator of pantothenate kinases.
Investigational
Matched Description: … BBP-671 is a small molecule activator of pantothenate kinases. …
Inhibitor of P38 Kinase
Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.
Experimental
Matched Description: … Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. ... These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … A chemically stable, cytidine analog that displays anti-tumor properties. ... It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
Virginiamycin S1
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
Experimental
Matched Description: … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae ... It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … IR208 is currently undergoing Phase II
studies in a 200-patient trial. ... IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation. …
Idraparinux
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Description: … As a result, Sanofi stopped the development of the drug. ... Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X …
Benzoctamine
Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.
Experimental
Matched Description: … Benzoctamine is a drug with two main uses. ... It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. …
Surotomycin
Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other...
Investigational
Matched Description: … Surotomycin has a fourfold greater in vitro potency than vancomycin against C. ... It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents ... effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a …
Cinolazepam
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Experimental
Matched Description: … Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Farletuzumab
Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
Investigational
Matched Description: … Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, …
Displaying drugs 10776 - 10800 of 11778 in total